Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolution of olsalazine.

S C Truelove1

  • 1Gastroenterology Unit Radcliffe Infirmary, Oxford, U.K.

Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Sulfasalazine effectively reduces ulcerative colitis attacks by delivering 5-ASA to the colon. Olsalazine was developed as an improved drug, releasing two 5-ASA molecules without a carrier, enhancing ulcerative colitis maintenance therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrinolysis and the eosinophil count.

Clinical science·2014
Same author

Infective hepatitis.

Proceedings of the Conference of Army Physicians, Central Mediterranean Forces : held at the Institute superiore di sanita : Rome, 29th January to 3rd February 1945. Conference of Army Physicians, Central Mediterranean Forces (1945 : Is...·2010
Same author

Blood Groups and Secretor Status in Ulcerative Colitis.

British medical journal·2010
Same author

A documentary study of jaundice associated with syphilis treatment and blood transfusion.

British journal of social medicine·2010
Same author

Epidemiology of infective hepatitis among Allied troops in Italy.

British journal of social medicine·2010
Same author

Personal viewpoint: Hoist with my own petard!

Gut·1994
Same journal

Abstract from the 41st Nordic Gastroenterology Congress, 8-11 June 2010, Copenhagen, Denmark.

Scandinavian journal of gastroenterology. Supplement·2010
Same journal

Abstracts from the XL Nordic Meeting of Gastroenterology, June 8-11, 2009, Stavanger, Norway.

Scandinavian journal of gastroenterology. Supplement·2009
Same journal

Abstracts of the 39th Nordic Meeting of Gastroenterology, 30th Nordic Meeting of Digestive Endoscopy, 18th Nordic Meeting of Gastrointestinal Motility, and the Annual Endoscopy/Gastroenterology Nurses'/Assistants' Meeting Post-graduate course, 4-6 June 2008, Helsinki, Finland.

Scandinavian journal of gastroenterology. Supplement·2008
Same journal

Abstracts from the XXXVIII Nordic Meeting of Gastroenterology, XXIX Nordic Meeting of Digestive Endoscopy, XVII Nordic Meeting of Gastrointestinal Motility, 6-9 June 2007, Reykjavik, Iceland.

Scandinavian journal of gastroenterology. Supplement·2007
Same journal

Abstracts of the XXXVII Nordic Meeting of Gastroenterology, 3-5 May 2006, Vasteras, Sweden.

Scandinavian journal of gastroenterology. Supplement·2006
Same journal

Novel approaches in the outpatient care of patients with chronic inflammatory bowel disease.

Scandinavian journal of gastroenterology. Supplement·2006
See all related articles

Area of Science:

  • Gastroenterology and Pharmacology: Focuses on the therapeutic applications and metabolic pathways of drugs used in treating inflammatory bowel diseases.

Background:

  • Sulfasalazine, developed nearly 50 years ago, is a long-term maintenance therapy proven to substantially reduce recurrent ulcerative colitis attacks.
  • Oral administration of sulfasalazine results in its colonic bacteria-mediated cleavage into 5-aminosalicylic acid (5-ASA) and sulfapyridine.
  • 5-ASA is identified as the active therapeutic agent, while sulfapyridine acts as a carrier molecule.

Discussion:

  • The metabolism of sulfasalazine highlights the importance of targeted drug delivery to the colon for treating ulcerative colitis.
  • Sulfapyridine's role as a carrier, rather than an active therapeutic moiety, prompted the development of alternative drug formulations.
  • Understanding the breakdown products of sulfasalazine is crucial for optimizing anti-inflammatory drug design.

Related Experiment Videos

Key Insights:

  • 5-ASA is the primary active component responsible for the therapeutic benefits in ulcerative colitis treatment.
  • Sulfasalazine's efficacy is linked to its colonic delivery and subsequent release of 5-ASA.
  • The development of olsalazine aimed to improve upon sulfasalazine by delivering two molecules of 5-ASA without a carrier.

Outlook:

  • Olsalazine represents a targeted approach to ulcerative colitis therapy, maximizing 5-ASA delivery.
  • Future research may focus on further optimizing drug delivery systems for inflammatory bowel disease management.
  • The development of carrier-free 5-ASA prodrugs signifies advancements in pharmaceutical innovation for gastrointestinal disorders.